Weight Loss – Page 2

Scholar Rock’s SMA drug helps Zepbound patients retain muscle in phase 2 trial

4 months ago talkbio0Tagged apitegromab, GDF8 protein, human, Inhibitor, Lean Mass, muscle preservation, Obesity, Phase 2 trial, Scholar Rock, Spinal Muscular Atrophy, Weight Loss, Zepbound

Scholar Rock; apitegromab; SMA drug; Zepbound; tirzepatide; muscle preservation; obesity; weight loss; phase 2 trial; lean mass; myostatin inhibitor

Lilly Posts Encouraging Early-Stage Weight Loss Data on Amylin Candidate

4 months ago talkbio0Tagged Amylin Candidate, aspects of adverse effects, Clinical Data, early-stage trial, Eli, Eli Lilly, Eloralintide, Obesity, Weight Loss

Eli Lilly; eloralintide; amylin candidate; weight loss; early-stage trial; obesity drug; clinical data; side effects

Novo Nordisk Plans Phase 3 Trials for Next-Generation Obesity Drug Amycretin

4 months ago talkbio0Tagged amycretin, Clinical Trials, Glucagon-Like Peptide 1, Nordisk, Obesity, Oral cavity, Phase 3, Receptors, Islet Amyloid Polypeptide, subcutaneous, Weight Loss

Novo Nordisk; amycretin; obesity; clinical trials; Phase 3; GLP-1; amylin receptor; weight loss; subcutaneous; oral

Lilly says further head-to-head trial data back Zepbound over Novos Wegovy

5 months ago talkbio0Tagged Comparative Efficacy, Obesity, semaglutide, SURMOUNT-5 Trial, tirzepatide, Weight Loss

Tirzepatide, Semaglutide, Weight Loss, Obesity Treatment, SURMOUNT-5 Trial, Comparative Efficacy

Lilly’s oral GLP-1 succeeds in first Phase III test, delivering promising weight loss

6 months ago talkbio0Tagged Diabetes Mellitus, Non-Insulin-Dependent, Glucagon-Like Peptide 1, Hemoglobin A1c measurement, Injectables, Oral cavity, orforglipron, Phase 3 Clinical Trials, Safety, Weight Loss

orforglipron, Glucagon-Like Peptide 1, Weight Loss, Oral cavity, orforglipron, Phase 3 Clinical Trials, Diabetes Mellitus, Non-Insulin-Dependent, Hemoglobin A1c measurement, Safety, Injectables

Veru’s Enobosarm Reduces Lean Mass Loss in Patients Taking Wegovy for Weight Reduction

9 months ago talkbio0Tagged Agonist, enobosarm, GLP-1 receptor, Lean mass preservation, Obesity, sarcopenic, semaglutide, Wegovy, Weight Loss

Enobosarm, Wegovy (semaglutide), Lean mass preservation, Weight loss, Sarcopenic obesity, GLP-1 receptor agonist

Novo Nordisk’s Obesity Drug Breakthrough: 22% Weight Loss at Week 36 Boosts Stock by 11%

9 months ago talkbio0Tagged 22%, amycretin, Drug Industry, next-gen, Nordisk, Obesity, semaglutide, Stock Surge, Weight Loss

Novo Nordisk, Obesity drug, 22% weight loss, Stock surge, Next-gen obesity treatment, Amycretin, Semaglutide, Pharmaceutical industry

Hengrui and Kailera’s Obesity Drug HRS9531 Shows Promising Results in Phase 2 Trial

9 months ago talkbio0Tagged GLP-1/GIP receptor dual agonist, Hengrui Pharmaceuticals, Kailera, Obesity, Phase 2 clinical trial, Weight Loss

HRS9531, Obesity treatment, GLP-1/GIP receptor dual agonist, Phase 2 clinical trial, Weight loss, Hengrui Pharmaceuticals, Kailera Therapeutics

GLP-1 Medications: Balancing Efficacy and Concerns Amidst Celebrity Endorsements and Rising Demand

9 months ago talkbio0Tagged agonists, aspects of adverse effects, Diabetes Mellitus, Non-Insulin-Dependent, Employer, Endorsements, Famous Persons, Financial cost, Glucagon-Like Peptide 1, Health Planning, Long-term Safety, Weight Loss

GLP-1 agonists, Weight loss, Type 2 diabetes, Celebrity endorsements, Side effects, Long-term safety, Cost implications, Employer health plans

CagriSema Achieves 22.7% Weight Loss in Phase 3 REDEFINE 1 Trial, Falling Short of 25% Target

10 months ago talkbio0Tagged cagrilintide, CagriSema, Nordisk, Obesity, Phase 3 REDEFINE 1 Trial, semaglutide, Weight Loss

CagriSema, Weight Loss, Phase 3 REDEFINE 1 Trial, Obesity Treatment, Novo Nordisk, Semaglutide, Cagrilintide